258 related articles for article (PubMed ID: 26574630)
1. Prognostic Value of Coexisting Lobular Carcinoma In Situ With Invasive Lobular Carcinoma.
Harbhajanka A; Lamzabi I; Syed S; Jain R; Ghai R; Reddy VB; Bitterman P; Gattuso P
Appl Immunohistochem Mol Morphol; 2016; 24(10):738-743. PubMed ID: 26574630
[TBL] [Abstract][Full Text] [Related]
2. The Pathologic Finding of Combined Lobular Carcinoma
Jean-Louis CJ; Masdon J; Smith B; Battles O; Dale P
Am Surg; 2017 May; 83(5):482-485. PubMed ID: 28541858
[TBL] [Abstract][Full Text] [Related]
3. Absence of lobular carcinoma in situ is a poor prognostic marker in invasive lobular carcinoma.
Mouabbi JA; Raghavendra AS; Bassett RL; Christgen M; Middleton L; Teshome M; Nasrazadani A; Hortobagyi G; Hassan A; Tripathy D; Layman RM
Eur J Cancer; 2023 Sep; 191():113250. PubMed ID: 37573674
[TBL] [Abstract][Full Text] [Related]
4. Comparison of the clinicopathological features of invasive ductal, invasive lobular, and mixed (invasive ductal + invasive lobular) carcinoma of the breast.
Zengel B; Yararbas U; Duran A; Uslu A; Elıyatkın N; Demırkıran MA; Cengiz F; Şimşek C; Postacı H; Vardar E; Durusoy R
Breast Cancer; 2015 Jul; 22(4):374-81. PubMed ID: 23925582
[TBL] [Abstract][Full Text] [Related]
5. Frequent alterations of HER2 through mutation, amplification, or overexpression in pleomorphic lobular carcinoma of the breast.
Lien HC; Chen YL; Juang YL; Jeng YM
Breast Cancer Res Treat; 2015 Apr; 150(2):447-55. PubMed ID: 25773929
[TBL] [Abstract][Full Text] [Related]
6. Specific sites of metastases in invasive lobular carcinoma: a retrospective cohort study of metastatic breast cancer.
Inoue M; Nakagomi H; Nakada H; Furuya K; Ikegame K; Watanabe H; Omata M; Oyama T
Breast Cancer; 2017 Sep; 24(5):667-672. PubMed ID: 28108967
[TBL] [Abstract][Full Text] [Related]
7. Immunohistochemical features of multifocal and multicentric lobular breast carcinoma.
Ilić IR; Petrović A; Živković VV; Randjelović PJ; Stojanović NM; Radulović NS; Randjelović D; Ilić RS
Adv Med Sci; 2017 Mar; 62(1):78-82. PubMed ID: 28189947
[TBL] [Abstract][Full Text] [Related]
8. PIK3CA mutations are common in lobular carcinoma in situ, but are not a biomarker of progression.
Shah V; Nowinski S; Levi D; Shinomiya I; Kebaier Ep Chaabouni N; Gillett C; Grigoriadis A; Graham TA; Roylance R; Simpson MA; Pinder SE; Sawyer EJ
Breast Cancer Res; 2017 Jan; 19(1):7. PubMed ID: 28095868
[TBL] [Abstract][Full Text] [Related]
9. Synchronous lobular carcinoma in situ and invasive lobular cancer: marker or precursor for invasive lobular carcinoma.
Wallace AS; Xiang D; Hockman L; Arya M; Jeffress J; Wang Z; Dale PS
Eur J Surg Oncol; 2014 Oct; 40(10):1245-9. PubMed ID: 24857380
[TBL] [Abstract][Full Text] [Related]
10. Cadherin-catenin complex dissociation in lobular neoplasia of the breast.
Morrogh M; Andrade VP; Giri D; Sakr RA; Paik W; Qin LX; Arroyo CD; Brogi E; Morrow M; King TA
Breast Cancer Res Treat; 2012 Apr; 132(2):641-52. PubMed ID: 22080244
[TBL] [Abstract][Full Text] [Related]
11. [Prognostic value of estrogen receptor, progesterone receptor and human epidermal growth factor receptor-2 in node positive breast cancer patients treated by mastectomy].
Wang SL; Li YX; Song YW; Wang WH; Jin J; Liu YP; Liu XF; Yu ZH
Zhonghua Zhong Liu Za Zhi; 2010 Jul; 32(7):520-5. PubMed ID: 21029696
[TBL] [Abstract][Full Text] [Related]
12. Correlation of clinicopathologic parameters and immunohistochemical features of triple-negative invasive lobular carcinoma.
Harbhajanka A; Lamzabi I; Singh RI; Ghai R; Reddy VB; Bitterman P; Gattuso P
Appl Immunohistochem Mol Morphol; 2014 Jul; 22(6):e18-26. PubMed ID: 25003839
[TBL] [Abstract][Full Text] [Related]
13. The expression of ERalpha, ERbeta and PR in lobular carcinoma in situ of the breast determined using laser microdissection and real-time PCR.
Green AR; Young P; Krivinskas S; Rakha EA; Claire Paish E; Powe DG; Ellis IO
Histopathology; 2009 Mar; 54(4):419-27. PubMed ID: 19309393
[TBL] [Abstract][Full Text] [Related]
14. Is there a low-grade precursor pathway in breast cancer?
King TA; Sakr RA; Muhsen S; Andrade VP; Giri D; Van Zee KJ; Morrow M
Ann Surg Oncol; 2012 Apr; 19(4):1115-21. PubMed ID: 21935747
[TBL] [Abstract][Full Text] [Related]
15. Associations between the standardized uptake value of (18)F-FDG PET/CT and the prognostic factors of invasive lobular carcinoma: in comparison with invasive ductal carcinoma.
Jung NY; Kim SH; Choi BB; Kim SH; Sung MS
World J Surg Oncol; 2015 Mar; 13():113. PubMed ID: 25889560
[TBL] [Abstract][Full Text] [Related]
16. Correlation of p16 Expression on Cancer and Stromal Cells With Clinicopathologic and Immunohistochemical Features of Lobular Breast Carcinoma.
Harbhajanka A; Lamzabi I; Bitterman P; Reddy VB; Ghai R; Gattuso P
Appl Immunohistochem Mol Morphol; 2019 Oct; 27(9):658-662. PubMed ID: 31592814
[TBL] [Abstract][Full Text] [Related]
17. Hormone receptors and HER2 expression in primary breast carcinoma and corresponding lymph node metastasis: do we need both?
Raica M; Cîmpean AM; Ceausu RA; Fulga V; Nica C; Rudico L; Saptefrati L
Anticancer Res; 2014 Mar; 34(3):1435-40. PubMed ID: 24596391
[TBL] [Abstract][Full Text] [Related]
18. Mitotic score and pleomorphic histology in invasive lobular carcinoma of the breast: impact on disease-free survival.
Mukhtar RA; Krings G; Chen YY; Mamounas ME; Fahrner-Scott K; Wong J; Alvarado M; Ewing C; Esserman LJ; Rugo H
Breast Cancer Res Treat; 2020 May; 181(1):23-29. PubMed ID: 32240457
[TBL] [Abstract][Full Text] [Related]
19. [Lobular carcinoma in situ (LCIS): risk factor and precursor of invasive lobular breast cancer].
Aulmann S; Penzel R; Schirmacher P; Sinn HP
Verh Dtsch Ges Pathol; 2007; 91():208-13. PubMed ID: 18314616
[TBL] [Abstract][Full Text] [Related]
20. The florid subtype of lobular carcinoma in situ: marker or precursor for invasive lobular carcinoma?
Bagaria SP; Shamonki J; Kinnaird M; Ray PS; Giuliano AE
Ann Surg Oncol; 2011 Jul; 18(7):1845-51. PubMed ID: 21287281
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
